May 7, 2018 / 8:44 PM / 2 months ago

BRIEF-MacroGenics Posts Qtrly Net Loss Per Common Share Of $1.34

May 7 (Reuters) - MacroGenics Inc:

* MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND 1ST QUARTER 2018 FINANCIAL RESULTS

* MACROGENICS - IN H2, SEES TO PROVIDE CLINICAL UPDATES ON FLOTETUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AML, ON COMBINATION OF ENOBLITUZUMAB WITH ANTI-PD-1 AGENT

* ANTICIPATE TWO OF CO’S ONCOLOGY PRODUCT CANDIDATES WILL MOVE INTO CLINICAL PIPELINE THIS YEAR

* TOTAL REVENUE WAS $4.7 MILLION FOR QUARTER ENDED MARCH 31, 2018, COMPARED TO $2.1 MILLION

* QTRLY NET LOSS PER COMMON SHARE $1.34

* Q1 EARNINGS PER SHARE VIEW $-1.08, REVENUE VIEW $6.8 MILLION — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below